LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) is a clinical-stage pharmaceutical company focused on developing new cancer therapies. The company’s lead clinical compound is LB-100, a first-in-class PP2A inhibitor that has demonstrated it is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.
The company is advancing a pioneering effort in an emerging field of cancer biology called activation lethality, which is developing a new treatment paradigm covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. LIXTE sponsored the Good Health Mind, Body And Soul Summit at Morehouse College, reflecting the company’s engagement with health education and community wellness initiatives.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://menafn.com/1110632124/Biomednewsbreaks-LIXTE-Biotechnology-Holdings-Inc-NASDAQ-LIXT-Sponsors-Good-Health-Mind-Body-And-Soul-Summit-At-Morehouse-College